Chemotherapy Induced Neutropenia (Toxicology) – Pharmaceutical and Healthcare Pipeline Guide, H2, 2017

Posted on 2017-07-31 by Mark Hub in Healthcare // 0 Comments

Albany, NY, 2017-Jul-31 — /EPR Network/ —Market Research Hub’s latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape. Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.

Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1256889

Market Research Hub’s Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 4, 2, 5, 6, 9, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Market Research Hubs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope:
– The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).
– The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)

Reasons to buy:
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report with TOC @ http://www.marketresearchhub.com/report/chemotherapy-induced-neutropenia-pipeline-review-h2-2017-report.html

Table of Content:

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Market Research Hub Report Coverage 6
Chemotherapy Induced Neutropenia – Overview 7
Chemotherapy Induced Neutropenia – Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Chemotherapy Induced Neutropenia – Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Chemotherapy Induced Neutropenia – Companies Involved in Therapeutics Development 25
BeyondSpring Pharmaceuticals Inc 25
Biocon Ltd 25
Bolder Biotechnology Inc 26
Cellerant Therapeutics Inc 26
Chong Kun Dang Pharmaceutical Corp 27
Cinfa Biotech SL 27
Dr. Reddy’s Laboratories Ltd 28
Gene Techno Science Co Ltd 28
Generon (Shanghai) Corp Ltd 29
Genexine Inc 29
GlycoMimetics Inc 30
Hanmi Pharmaceuticals Co Ltd 30
Intas Pharmaceuticals Ltd 31
Lupin Ltd 31
Mycenax Biotech Inc 32
Myelo Therapeutics GmbH 32
Nohla Therapeutics Inc 33
Octapharma AG 33
Pangen Biotech Inc. 34
Pfenex Inc 34
Pfizer Inc 35
Reliance Life Sciences Pvt Ltd 35
Richter Gedeon Nyrt 36
Sandoz International GmbH 36
USV Pvt Ltd 37

Make an Enquiry @ http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1256889

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of Research Reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick